Fri, Jan 30, 2015, 11:28 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

johnodod 4 posts  |  Last Activity: Jan 15, 2015 10:10 AM Member since: Jun 28, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • johnodod by johnodod Jan 15, 2015 10:10 AM Flag

    Vical has zero chance of capitalizing on the success they had with HUMAN Ebola trials in the United States. Fauci doesn't like Vical and he is too busy being on TV to actually get something out of the pipeline anyway. He funds tests to say they're working on the problem but never seems to solve anything or sustain the effort after the cameras are gone.
    Japan meanwhile is an economic basket case with national debt that is 200% of GDP. The rapid regulatory approval that is a vast cultural change for Japan is fueled by the panic of a national crisis. They better develop strong positions in new industries or the standard of living will continue to decline but at a much faster rate.
    Vical has an EXCELLENT chance to get this approved in Japan with their Japanese partner. Moreover, the market is not in any developed country so a U.S. approved product has no advantage at all. Vaxfectin can show value and make it more suitable for partnerships off of this so there is money to be made from this.

  • johnodod by johnodod Dec 23, 2014 11:54 AM Flag

    Vical's Board of Directors must be the Bored Directors after letting Vijay continue to fail without consequence, while investors are taken over the cliff. It's been years....literally, years, since Vijay started touting Vaxfectin and the universal CMV vaccine as partner bait. Success would change the investment results while the Herpes and CMV transplant trials continue. Vical has produced nothing except investor presentation slides touting the potential.....there have been no deals. Vijay needs to be fired or the BOD should be replaced. Vical is worth more dead than alive with this leadership.

  • Reply to

    Non-Existant Investor relations

    by ephisus11 Dec 4, 2014 11:38 AM
    johnodod johnodod Dec 4, 2014 5:33 PM Flag

    I can vouch for that as true. I got the San Diego Union Tribune to do a story on their 2006 Ebola vaccine and they wouldn't return repeated calls from the reporter.

  • President Barack Obama’s pending request for an additional $6.18 billion to fight Ebola puts a new price tag on the vast scale the federal government contemplates in fighting the deadly viral epidemic.

    With several San Diego-based efforts for Ebola treatments and diagnostics already in progress, local biotech companies and researchers are likely to get a chunk of that money.

    Hundreds of millions of dollars for various responses against the disease, such as dispatching U.S. military personnel to build Ebola-specific hospitals in West Africa, have been approved in recent months.

    The new request encompasses major domestic initiatives in addition to those earlier projects. The latest mix includes programs to develop experimental therapies and efforts to train and fund more than 50 Ebola treatment centers.

    In the president’s new proposal to Congress, the Biomedical Advanced Research and Development Authority, or BARDA, would receive $157 million for “immediate response to manufacture vaccines and synthetic therapeutics for use in clinical trials.”

    That amount and other aspects of the funding request have drawn scrutiny from congressional Republicans, who said the measure needs further examination to make sure the money would be well spent.

    “The president’s request deserves study, and I want to ensure that any new money is necessary and appropriately focused,” Rep. Darrell Issa, R-Vista, said Tuesday.

    “We have engaged in efforts to combat Ebola in Africa and need to see what immediate needs new funds can address,” he wrote in an email to U-T San Diego.

    Until this year, Ebola had not received much attention in the United States aside from a few headlines generated by sporadic outbreaks in Africa or publicity in books like “The Hot Zone” in 1994 or the 2011 movie “Contagion.” Likewise, drug and vaccine development has been sporadic.

    San Diego-based Vical had researched an Ebola vaccine and reported positive results from Phase I clinical testing in February

VICL
1.040.00(0.00%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.